This study will describe and compare the rates of asthma exacerbations observed between 12-month pre-switch and 12-month post-switch periods among participants switching to AIRSUPRA. Other outcome measures included in this study are asthma-related oral corticosteroid (OCS) use, and asthma exacerbation-related healthcare resource utilization (HCRU), healthcare cost, and patient reported outcomes (PROs).
ANCHOR
Assessment of Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
Asthma
All genders
18+
Recruiting now
Overview
Principal Investigator: Michael Paasche -Orlow
Contact Us
Jasmine Malave
Study details
Inclusion Criteria
- 1. 18 years of age or older
2. At least one healthcare visit related to asthma within the last 12 months - 3. At least one filled prescription of rescue inhaler for asthma within the last 12 months
4. At least one asthma attack within the last 12 months - 5. Have both medical and pharmacy insurance coverage.
Exclusion Criteria
- 1. Patients with major respiratory diagnoses within the last 12 months
2. Chronic use of oral corticosteroids (i.e., prednisone, etc) - 3. History of cancer (except skin cancer) still unresolved in the last 12 months
4. Pregnant, breastfeeding or planning to become pregnant within 12 months - 5. Already using AIRSUPRA
Study Requirements
Study participants will be provided with a new FDA-approved asthma rescue inhaler, AIRSUPRA™, for 12 months in place of their current rescue inhaler for asthma treatment